Some manufacturers are falling behind. Novavax has had production problems. Johnson & Johnson, which initially planned for one billion doses this year, has made slightly more than 103 million, Mr. Krellenstein said, citing data from the scientific intelligence firm Airfinity. That is in part because its contract manufacturer, Emergent BioSolutions, ruined up to 15 million…
